sale organ exceed our/consensu estim
led broad-bas strength across medsurg orthoped
neurotech/spin ep top our/consensu sale beat
oper margin line y/i vs estim mako
placement vs versu estim instrument medic
biggest standout reflect solid execut solid capital-expenditure environ
note non-profit hospit survey report rais guidanc
revenu organ previous ep
impact notic initi rosa launch growth remain
balanc geograph manag highlight solid perform europ
emerg market
market comment overal price y/i better ortho
price posit primarili due favor mix
ou price joint-replac combin syk/jnj knee/hip growth
estim vs combin comp easier
rel line sequenti
orthopedics/spin forty-four mako robot us place vs us
mako total knee procedur exceed y/i line
growth hip acceler cup increas util mako
hip spine remain rel drag growth due integr management
note improv re-affirmed mid-single-digit growth
medsurg instrument led medsurg continu benefit realign
salesforc solid growth power tools/wast manag product management
indic extrapol particularli outsiz perform endo growth
slightli higher vs vs ramp new
camera acceler upsid driver core solid
capit growth
guidanc organ sale growth outlook ex acquisit fx rais
ep rais
one extra sell day oper margin expans target remain
despit deal-rel dilut expect year fx impact
headwind expect ep vs previou
estim sale increas close organ y/i growth
led higher medsurg beat rais guidanc
ep increas assum net oper
margin expans forecast sales/ep growth rais
estim market multipl expans price target rise
year price histori
medic devic compani
found headquart
kalamazoo mi compani
orthopaed medsurg equip
analyst certif import disclosur see disclosur
divers growth opportun across segment
geograph solid execut posit rate
share perform valuat trade ep
estim versu peer price target impli
price-to-earnings in-line peer current trail multipl
underli revenu growth close led neurotech
endoscopi new camera knee instrument
oper margin underli ctg cost
on-going launch triathlon knee mako robot
camera launch endoscopi
launch trauma
on-going cup launch hip
mako procedur use increas joint outsid knee
better expect margin leverag
better us capital-expenditure environ lead medsurg expect
slowdown hospit capit spend slow medsurg segment
greater expect price pressur
competit product launch knee impact growth more/soon
expect
price target driven dcf wacc ebitda termin growth impli price-to-earnings
multipl ep
risk price target includ wors expect price pressur key market tough competit slowdown hospit
compani report oppenheim co estim
million except per share data
neurotechnolog spine
neurotechnolog spine
